Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 681-689

  Nekhlyudov, Larissa ^a,b   Li, Lingling ^a   Ross Degnan, Dennis ^a   Wagner, Anita K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

Adherence; Adjuvant hormonal therapy; Breast cancer

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVOR; DRUG SUBSTITUTION; DRUG USE; EARLY CANCER; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH INSURANCE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; THERAPY; TREATMENT DURATION; TREATMENT GAP; TREATMENT INTERRUPTION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG SUBSTITUTION; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASM STAGING; TAMOXIFEN;

EID: 82955195816     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1703-z     Document Type: Article

References (24)

1. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish breast cancer cooperative group. J Natl Cancer Inst 88:1543-1549 (1996)
2. Baum M, Buzdar AU, Cuzick J, Forbes J, Houghton J, Klijn JGM et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC ran-domised trial. The Lancet 359(9324):2131-2139 (Pubitemid 34694019)
3. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss Jetal (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aro-matase inhibitors versus tamoxifen. J Clin Oncol 28:509-518
4. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619-629 (Pubitemid 46224240)
5. Aiello EJ, Buist DS, Wagner EH, Tuzzio L, Greene SM, Lame-rato LE et al (2008) Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat 107:397-403 (Pubitemid 351172110)
6. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadher-ence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606 (Pubitemid 46621892)
7. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Research Treat 99:215-220 (Pubitemid 44268270)
8. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322-328 (Pubitemid 32112842)
9. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309-3315 (Pubitemid 41103687)
10. Owusu C, Buist DSM, Field TS, Lash TL, Thwin SS, Geiger AM et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-breast cancer. J Clin Oncol 26:549-555 (Pubitemid 351264347)
11. Partridge AH, La Fountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anas-trozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556-562 (Pubitemid 351264348)
12. Ziller V, Kalder M, Albert US, Holzhauer W, Miller M, Wagner U et al (2009) Adherence to adjuvant endocrine therapy in post-menopausal women with breast cancer. Ann Oncol 20:401-402
13. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27:3445-3451
14. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J Clin Oncol 28:4120-4128
15. Sedjo RL, Devine S (2010) Predictors of non-adherence to aro-matase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125:191-200
16. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45:431-439
17. Barron TI, Connolly R, Bennett K, Freely J, Kennedy J (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109:832-839 (Pubitemid 46333524)
18. Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL (2004) An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 39(6 Pt 1):1733-1749 (Pubitemid 39601249)
19. Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN et al (2002) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40(Supplement):IV55-IV61
20. Schneeweiss S, Wang PS, Avorn J, Maclure M, Levin R, Glynn RJ (2004) Consistency of performance ranking of comorbidity adjustment scores in Canadian and US utilization data. J Gen Intern Med 19:444-450 (Pubitemid 38638905)
21. Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71:1-9
22. Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56-66
23. Pezzin LE, O'Niel MB, Nattinger AB (2009) The economic consequences of breast cancer adjuvant hormonal treatments. J Gen Intern Med 24(Suppl 2):S446-S450
24. Neugut AI, Subar M, Ty Wilde E, Stratton S, Brouse CH, Hillyer GC et al (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534-2542